NCT04813796View on ClinicalTrials.gov

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

July 25, 2023

Study Completion Date

July 25, 2023

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

mRNA-1283

Sterile liquid for injection

BIOLOGICAL

mRNA-1273

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (5)

32934

Optimal Research Melbourne, LLC, Melbourne

61614

Optimal Research Illinois, LLC, Peoria

78705

Optimal Research Texas, LLC, Austin

85224

Synexus Clinical Research US Phoenix Southeast, Inc., Chandler

92108

Optimal Research San Diego, LLC, San Diego

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT04813796 - A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 | Biotech Hunter | Biotech Hunter